Switch theme
Sign up to access all valuation multiples
Caplin Point Laboratories Ltd is an India-based pharmaceutical company. It is engaged in the manufacturing and marketing of pharmaceutical products. The company's key products include tablets, capsules, injections (liquid and lyophilized, prefilled syringes), ophthalmic solutions, liquid orals, soft gel capsules, ointments, creams, gels, powders for injections, suppositories, ovules, pre-mix bag formulations, inhalers, sprays, and IV infusions. It also provides pharmaceutical formulations in specialized injectable dosage forms and Ophthalmic drops.
1990
859
LTM Revenue $229M
LTM EBITDA $78.8M
$1.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Caplin Point Laboratories has a last 12-month revenue (LTM) of $229M and a last 12-month EBITDA of $78.8M.
In the most recent fiscal year, Caplin Point Laboratories achieved revenue of $227M and an EBITDA of $87.1M.
Caplin Point Laboratories expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Caplin Point Laboratories valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $229M | XXX | $227M | XXX | XXX | XXX |
| Gross Profit | $229M | XXX | $137M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 60% | XXX | XXX | XXX |
| EBITDA | $78.8M | XXX | $87.1M | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | 38% | XXX | XXX | XXX |
| EBIT | $81.7M | XXX | $68.0M | XXX | XXX | XXX |
| EBIT Margin | 36% | XXX | 30% | XXX | XXX | XXX |
| Net Profit | $64.5M | XXX | $62.8M | XXX | XXX | XXX |
| Net Margin | 28% | XXX | 28% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Caplin Point Laboratories's stock price is INR 2152 (or $25).
Caplin Point Laboratories has current market cap of INR 164B (or $1.9B), and EV of INR 154B (or $1.8B).
See Caplin Point Laboratories trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.8B | $1.9B | XXX | XXX | XXX | XXX | $0.85 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Caplin Point Laboratories has market cap of $1.9B and EV of $1.8B.
Caplin Point Laboratories's trades at 8.2x EV/Revenue multiple, and 21.6x EV/EBITDA.
Equity research analysts estimate Caplin Point Laboratories's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Caplin Point Laboratories has a P/E ratio of 29.7x.
See valuation multiples for Caplin Point Laboratories and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.9B | XXX | $1.9B | XXX | XXX | XXX |
| EV (current) | $1.8B | XXX | $1.8B | XXX | XXX | XXX |
| EV/Revenue | 7.9x | XXX | 8.2x | XXX | XXX | XXX |
| EV/EBITDA | 22.9x | XXX | 21.6x | XXX | XXX | XXX |
| EV/EBIT | 22.1x | XXX | 27.5x | XXX | XXX | XXX |
| EV/Gross Profit | 7.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | 29.7x | XXX | 31.7x | XXX | XXX | XXX |
| EV/FCF | 49.5x | XXX | 68.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCaplin Point Laboratories's last 12 month revenue growth is 17%
Caplin Point Laboratories's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Caplin Point Laboratories's rule of 40 is 55% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Caplin Point Laboratories's rule of X is 76% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Caplin Point Laboratories and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 17% | XXX | 17% | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | 38% | XXX | XXX | XXX |
| EBITDA Growth | 21% | XXX | 11% | XXX | XXX | XXX |
| Rule of 40 | 55% | XXX | 55% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 76% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 30% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Caplin Point Laboratories acquired XXX companies to date.
Last acquisition by Caplin Point Laboratories was XXXXXXXX, XXXXX XXXXX XXXXXX . Caplin Point Laboratories acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Caplin Point Laboratories founded? | Caplin Point Laboratories was founded in 1990. |
| Where is Caplin Point Laboratories headquartered? | Caplin Point Laboratories is headquartered in India. |
| How many employees does Caplin Point Laboratories have? | As of today, Caplin Point Laboratories has 859 employees. |
| Is Caplin Point Laboratories publicy listed? | Yes, Caplin Point Laboratories is a public company listed on BOM. |
| What is the stock symbol of Caplin Point Laboratories? | Caplin Point Laboratories trades under 524742 ticker. |
| When did Caplin Point Laboratories go public? | Caplin Point Laboratories went public in 2001. |
| Who are competitors of Caplin Point Laboratories? | Similar companies to Caplin Point Laboratories include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Caplin Point Laboratories? | Caplin Point Laboratories's current market cap is $1.9B |
| What is the current revenue of Caplin Point Laboratories? | Caplin Point Laboratories's last 12 months revenue is $229M. |
| What is the current revenue growth of Caplin Point Laboratories? | Caplin Point Laboratories revenue growth (NTM/LTM) is 17%. |
| What is the current EV/Revenue multiple of Caplin Point Laboratories? | Current revenue multiple of Caplin Point Laboratories is 7.9x. |
| Is Caplin Point Laboratories profitable? | Yes, Caplin Point Laboratories is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Caplin Point Laboratories? | Caplin Point Laboratories's last 12 months EBITDA is $78.8M. |
| What is Caplin Point Laboratories's EBITDA margin? | Caplin Point Laboratories's last 12 months EBITDA margin is 34%. |
| What is the current EV/EBITDA multiple of Caplin Point Laboratories? | Current EBITDA multiple of Caplin Point Laboratories is 22.9x. |
| What is the current FCF of Caplin Point Laboratories? | Caplin Point Laboratories's last 12 months FCF is $36.5M. |
| What is Caplin Point Laboratories's FCF margin? | Caplin Point Laboratories's last 12 months FCF margin is 16%. |
| What is the current EV/FCF multiple of Caplin Point Laboratories? | Current FCF multiple of Caplin Point Laboratories is 49.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
